1006 GMT - AstraZeneca is among the most mentioned companies across news items over the past six hours, according to Factiva data, after the company posted a higher first-quarter profit which beat analysts' expectations. The Anglo-Swedish pharma giant also backed its guidance for the full year, saying that it expects total revenue to increase by a low-to-mid single-digit percentage. Excluding Covid-19 medicines, total revenue is expected to increase by a low double-digit percentage, and core EPS is expected to increase by a high single-digit to low double-digit percentage, AstraZeneca said. Net profit for the quarter came in at $1.80 billion, up from $388 million the year prior, and beating analysts' expectations of $1.52 billion. Revenue, however, was hurt by a decline of $1.46 billion in sales of Covid-19 medicines, and came in at $10.88 billion from $11.39 billion in the same quarter of 2022, the company said. Dow Jones & Co. owns Factiva. (cecilia.butini@wsj.com)

 

(END) Dow Jones Newswires

April 27, 2023 06:21 ET (10:21 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024 Click aqui para mais gráficos Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024 Click aqui para mais gráficos Astrazeneca.